Investment Analysts’ Recent Ratings Updates for BridgeBio Oncology Therapeutics (BBOT)

Several analysts have recently updated their ratings and price targets for BridgeBio Oncology Therapeutics (NASDAQ: BBOT):

• 9/12/2026 – BridgeBio Oncology Therapeutics was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 9/11/2026 – BridgeBio Oncology Therapeutics had its price target lowered by JPMorgan Chase & Co. from $25.00 to $23.00. They now have an “overweight” rating on the stock.
• 9/10/2026 – BridgeBio Oncology Therapeutics had its price target lowered by Leerink Partners to $27.00. They now have an “outperform” rating on the stock.
• 9/9/2026 – BridgeBio Oncology Therapeutics had its price target lowered by Raymond James Financial, Inc. from $24.00 to $22.00. They now have an “outperform” rating on the stock.
• 9/9/2026 – BridgeBio Oncology Therapeutics had its price target lowered by Stifel Nicolaus from $23.00 to $15.00. They now have a “buy” rating on the stock.
• 9/9/2026 – BridgeBio Oncology Therapeutics had its price target lowered by Canaccord Genuity Group Inc. from $23.00 to $20.00. They now have a “buy” rating on the stock.
• 9/9/2026 – BridgeBio Oncology Therapeutics had its “outperform” rating reaffirmed by Wedbush. They now have a $25.00 price target on the stock.
• 8/14/2026 – BridgeBio Oncology Therapeutics had its price target lowered by JPMorgan Chase & Co. from $27.00 to $25.00. They now have an “overweight” rating on the stock.
• 7/18/2026 – BridgeBio Oncology Therapeutics was upgraded by Wall Street Zen from “strong sell” to “sell”.

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.